Year: 2023

FUJIREBIO_CMYK

Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only

GENT, Belgium & MALVERN, Pa. & TOKYO--(BUSINESS WIRE)--#IVD--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability...